4 Citations (Scopus)


Glucocorticoid-induced diabetes mellitus (GIDM) is a well-known and common metabolic side effect of glucocorticoid (GC) treatment. The risk of developing GIDM in non-diabetic patients who receive systemic GCs, was evaluated in a metanalysis and found to be 18.6%. GIDM is potential life-threatening, and hyperglycaemia, even mild, in hospitalized patients is associated with both increased mortality and increased morbidity. Often, insulin is the preferred treatment option. However, insulin is a high-risk drug and to patients without previously known diabetes, initiation of insulin therapy requires training in blood glucose measurements and insulin injections.

Original languageEnglish
Article numbere13529
JournalInternational Journal of Clinical Practice
Issue number8
Publication statusPublished - Aug 2020


Dive into the research topics of 'Oral Treatment of Glucocorticoid-Induced Diabetes Mellitus: A Systematic Review'. Together they form a unique fingerprint.

Cite this